Apalutamide for the treatment of metastatic hormone-sensitive prostate cancer:a rapid health technology assessment
Objective To evaluate the efficacy,safety,and economy of apalutamide in the treatment of metastatic hor-mone-sensitive prostate cancer(mHSPC),as well as to provide theoretical guidance of rational clinical application.Methods The databases including PubMed,Embase,the Cochrane Library,CNKI,Wanfang,and other databases were searched.Mean-while,the database of health technology assessment(HTA),eligible systematic reviews/meta-analyses,economic studies,and HTA reports were included.Two researchers independently identified the literatures and extracted data.Finally,qualita-tive analysis was used to describe the research results.Results A total of 4 meta-analyses and 5 economic studies were includ-ed.The results showed that compared with androgen-deprivation therapy(ADT)alone,apalutamide combined with ADT can significantly increase the survival time of patients with good results and generally lower incidence of adverse reactions.Due to its high price,it is not cost-effective compared to other combination treatment options.Conclusion Apalutamide combined with ADT in the treatment of mHSPC has good efficacy and safety,and it can be economical if the price of apalutamide is re-duced by more than 50%.
apalutamidemetastatic hormone-sensitive prostate cancerandrogen-deprivation therapyrapid health technology assessment
NETL
NSTL
万方数据
